A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #351

Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.

Al-Dulaimi S, Thomas R, Matta S, et al. Biogerontology. 2025.
Weak / noneIn vitroMentions: Epitalon

Editor's note

This in-vitro study reports that Epitalon extended telomere length in human cell lines in a dose-dependent way — in normal breast epithelial and fibroblast cells via upregulation of hTERT and telomerase, and in breast cancer cell lines largely through the alternative lengthening of telomeres (ALT) pathway. That mechanistic split is the study's most interesting claim, and it aligns with Epitalon's proposed role as a telomerase activator. But these are isolated cells in culture, not animals or people, so the results are mechanistic signals only and cannot speak to whether Epitalon influences aging or is safe in vivo. The cancer-cell finding also cuts two ways: telomere lengthening in malignant cells is not obviously desirable, a caution worth noting for a compound marketed for longevity. Note too that a published correction attaches to this paper and should be read with it. Preclinical result; human data are needed before any clinical conclusions can be drawn.

Plain-language abstract

Telomeres are protective caps on the ends of chromosomes that shorten as cells age, and keeping them longer has been linked to healthier aging. This laboratory study tested Epitalon, a four-amino-acid peptide, on human cells grown in dishes: normal breast and connective-tissue cells, and breast cancer cell lines. After treating the cells, the researchers measured telomere length and the activity of telomere-building machinery. In the normal cells, Epitalon lengthened telomeres in a dose-dependent way by increasing production of an enzyme called telomerase (and its component hTERT). In the cancer cells, telomeres also lengthened, but mainly through a different route called ALT (alternative lengthening of telomeres); this ALT effect was mostly specific to the cancer cells. The authors conclude that Epitalon can extend telomeres in normal human cells by boosting telomerase. Because this was done only in cultured cells, it does not show what Epitalon does in animals or people. (A correction to this paper has since been published.)